Iovance Biotherapeutics, Inc. (IOVA)

NASDAQ: IOVA · Real-Time Price · USD

14.45

+3.46 (31.48%)

At close: Sep 29, 2026, 4:00 PM EDT

14.42

-0.03 (-0.20%)

After-hours: Sep 29, 2026, 7:59 PM EDT

Iovance Biotherapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	324.97	263.5	164.07	1.19	-	-
Revenue Growth	34.55%	60.60%	13698.99%	-	-	-
Gross Profit	157.29	90.32	70.82	0.16	-	-
Operating Income	-296.17	-398.21	-395.28	-460.56	-398.88	-342.7
Net Income	-289.52	-390.98	-372.18	-444.04	-395.89	-342.25
Earnings Per Share	-0.71	-1.09	-1.28	-1.89	-2.49	-2.23
EPS Growth	-	-	-	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Amtagvi	273.32	220.02	103.57	-
Proleukin	51.65	43.48	60.5	1.19
Revenue (Total)	324.97	263.5	164.07	1.19

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	297.67	296.98	323.78	279.87	471.85	504.41
Total Debt	46	49.44	58.26	75.86	85.45	71.53
Net Cash (Debt)	251.67	247.54	265.52	204.01	386.4	432.88
Net Cash Growth	1.47%	-6.77%	30.15%	-47.20%	-10.74%	-25.08%
Net Cash Per Share	0.61	0.69	0.92	0.87	2.43	2.82

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-264.18	-302.41	-352.98	-361.82	-292.76	-227.94
Capital Expenditures	-32.21	-33.84	-11.07	-22.29	-20.43	-37.57
Free Cash Flow	-296.4	-336.24	-364.05	-384.11	-313.18	-265.52
Free Cash Flow Growth	-	-	-	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	48.40%	34.28%	43.17%	13.12%	-	-
Operating Margin	-91.14%	-151.12%	-240.92%	-38734.99%	-	-
Pretax Margin	-90.40%	-149.16%	-228.56%	-37638.02%	-	-
Profit Margin	-89.09%	-148.38%	-226.84%	-37345.42%	-	-
FCF Margin	-91.21%	-127.61%	-221.89%	-32305.30%	-	-

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PS Ratio	20.14	4.11	13.75	1749.89	-	-